This ‘Universal Vaccine’ Could Stop Future Pandemics Before They Begin

  • تاريخ النشر: الجمعة، 12 يونيو 2026 زمن القراءة: دقيقة قراءة

Needle-free vaccine targets multiple coronaviruses and advances to larger trials

It Targets a Whole Coronavirus Family

Artificial Intelligence Designed the Active Component

The First Human Trial Included 39 Volunteers

The Vaccine Passed Its Initial Safety Test

It Triggered Broad Immune Responses

It Was Delivered Without a Needle

The Technology Could Reduce Constant Reformulation

It Could Be Adapted to Other Virus Groups

It Cannot Yet Be Called Pandemic-Proof

A Larger Phase 2 Trial Comes Next

  • 1 / 10
مقالات ذات صلة
The Most Profitable Industries of the Future
7 Tips to Help You Before Buying a New Laptop
The Future of Air Travel Might Surprise You

Scientists have completed the first human trial of a vaccine designed to protect against an entire family of coronaviruses rather than one known strain. Developed by the University of Cambridge and its spin-out company DIOSynVax, the experimental vaccine uses computer modelling and machine learning to anticipate viral threats before they spread widely.

The early results are promising, but the vaccine is not yet proven to prevent infection, serious illness or future pandemics. The Phase 1 study primarily tested safety and immune responses in a small group, with larger trials still required before the technology can approach public use.

مواضيع ذات صلة